Novartis
1,661
53
104
1,209
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.2%
236 terminated/withdrawn out of 1661 trials
83.7%
-2.8% vs industry average
41%
687 trials in Phase 3/4
39%
467 of 1209 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1661)
Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)
Role: collaborator
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Role: collaborator
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Role: collaborator
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Role: collaborator
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Role: collaborator
Pan Tumor Rollover Study
Role: collaborator
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
Role: collaborator
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Role: collaborator
Overcoming Racial Disparities in Screening Mammography
Role: collaborator
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Role: collaborator
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Role: collaborator
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
Role: collaborator
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Role: collaborator
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Role: collaborator
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
Role: collaborator
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Role: collaborator
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
Role: collaborator
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Role: collaborator
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Role: collaborator
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
Role: collaborator